A multicenter randomized study in early rheumatoid arthritis to compare active conventional therapy versus three biological treatments: 24 week efficacy results of the NORD-STAR trial

M. L. Hetland, E. A. Haavardsholm, A. Rudin, D. Nordström, M. Nurmohamed, B. Gudbjornsson, J. Lampa, K. Hørslev-Petersen, T. Uhlig, G. Gröndal, M. Ǿstergaard, M. Heiberg, J. Twisk, S. Krabbe, K. Lend, I. Olsen, J. Lindqvist, A. K. H. Ekwall, K. L. Grøn, M. C. KapetanovicF. Faustini, R. Tuompo, T. Lorenzen, G. Cagnotto, E. Baecklund, O. Hendricks, D. Vedder, T. Sokka-Isler, T. Husmark, M. K. A. Ljosa, E. Brodin, T. Ellingsen, A. Soderbergh, M. Rizk, r A. Reckner, P. Larsson, L. Uhrenholt, S. A. Just, D. Stevens, T. B. Laurberg, G. Bakland, R. Van Vollenhoven

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Abstract

Background: The optimal first-line treatment of patients (pts) with early rheumatoid arthritis (RA) is yet to be established.Objectives: The primary aim was to assess and compare the proportion of pts who achieved remission with active conventional therapy (ACT) and with three different biologic therapies after 24 wks. Secondary aims were to assess and compare other efficacy measures.Methods: The investigator-initiated NORD-STAR trial (NCT01491815) was conducted in the Nordic countries and Netherlands. In this multicenter, randomized, open-label, blinded-assessor study pts with treatment-naive, early RA with DAS28gt;3.2, and positive RF or ACPA, or CRP gt;10mg/L were randomized 1:1:1:1. Methotrexate (25 mg/week after one month) was combined with: 1) (ACT): oral prednisolone (tapered quickly); or: sulphasalazine, hydroxychloroquine and mandatory intra-articular (IA) glucocorticoid (GC) injections in swollen joints lt;wk 20; 2) certolizumab 200 mg EOW SC (CZP); 3) abatacept 125 mg/wk SC (ABA); tocilizumab 162 mg/wk SC (TCZ). IA GC was allowed in all arms lt;wk 20. Primary outcome was clinical disease activity index remission (CDAI
Original languageEnglish
Article numberOP0018
JournalAnnals of the Rheumatic Diseases
Volume79
Issue numberSuppl. 1
Pages (from-to)13-14
Number of pages2
ISSN0003-4967
DOIs
Publication statusPublished - 2020
Externally publishedYes
EventAnnual European Congress of Rheumatology: EULAR 2020 (e-congress, online) - E-congress, online
Duration: 3 Jun 20203 Jun 2020
http://congress.eular.org/

Conference

ConferenceAnnual European Congress of Rheumatology: EULAR 2020 (e-congress, online)
LocationE-congress, online
Period03/06/202003/06/2020
Internet address

Cite this